Organovo
In Vitro Drug Response Assessments in ExVive™ 3D Bioprinted Tissue
Presenter: Dr. Jeff Irelan, Director, Scientific Applications, Organovo
Short Description:
Translation of preclinical data to clinical outcomes remains an ongoing challenge in drug development. ExVive™ 3D Bioprinted Human Liver and Kidney Tissues are positioned to bridge the gap by providing physiological tissue-like responses over extended time of in vitro culture through spatially-controlled, automated deposition of tissues-specific cell types. Examples demonstrating the utility of these models for assessing drug induced hepatotoxicity and renal toxicity, as well as modeling liver disease states such as steatosis, inflammation, and fibrosis will be presented.
Short Description:
Translation of preclinical data to clinical outcomes remains an ongoing challenge in drug development. ExVive™ 3D Bioprinted Human Liver and Kidney Tissues are positioned to bridge the gap by providing physiological tissue-like responses over extended time of in vitro culture through spatially-controlled, automated deposition of tissues-specific cell types. Examples demonstrating the utility of these models for assessing drug induced hepatotoxicity and renal toxicity, as well as modeling liver disease states such as steatosis, inflammation, and fibrosis will be presented.
